Federal Register / Vol. 83, No. 136 / Monday, July 16, 2018 / Notices 32871 

58 If under the firm’s preferred resolution strategy, 

any derivatives portfolios are transferred during the 

resolution period by way of a line of business sale 

(or similar transaction), then those portfolios should 

nonetheless be included within the firm’s potential 

residual portfolio analysis. 

of the resolution period; and (ii) if 

exercising such right would 

economically benefit the counterparty 

(‘‘counterparty-initiated termination’’). 

• Time horizon: The duration of the 

resolution period should be between 12 

and 24 months. The resolution period 

begins immediately after the parent 

company bankruptcy filing and extends 

through the completion of the preferred 

resolution strategy. 

A dealer firm’s analysis of its 

derivatives strategy should, at a 

minimum, take into account (i) the 

starting profile of its derivatives 

portfolios (e.g., nature, concentration, 

maturity, clearability, and liquidity of 

positions); (ii) the profile and function 

of the derivatives entities during the 

resolution period; (iii) the means, 

challenges, and capacity for managing 

and de-risking its derivatives portfolios 

(e.g., method for timely segmenting, 

packaging, and selling the derivatives 

positions; challenges with novating less 

liquid positions; re-hedging strategy); 

(iv) the financial and operational 

resources required to effect the 

derivatives strategy; and (v) any 

potential residual portfolio (further 

discussed below). In addition, the firm’s 

resolution plan should address the 

following areas in the analysis of its 

derivatives strategy: 

Forecasts of resource needs. The 

forecasts of capital and liquidity 

resource needs required to adequately 

support the firm’s derivatives strategy 

should be incorporated into the firm’s 

RCEN and RLEN estimates for its overall 

preferred resolution strategy. These 

include, for example, the costs and/or 

liquidity flows resulting from (i) the 

close-out of OTC derivatives, (ii) the 

hedging of derivatives portfolios, (iii) 

the quantified losses that could be incur 

due to basis and other risks that would 

result from hedging with only exchangetraded and centrally cleared instruments 

in a severely adverse stress 

environment, and (iv) the operational 

costs. 

Potential residual derivatives 

portfolio. A dealer firm’s resolution plan 

should include a method for estimating 

the composition of any potential 

residual derivatives portfolio 

transactions remaining at the end of the 

resolution period under its preferred 

resolution strategy. The method may be 

a combination of approaches (e.g., 

probabilistic and deterministic) but 

should demonstrate the dealer firm’s 

capabilities related to portfolio 

segmentation (discussed above). The 

dealer firm’s plan should also provide 

detailed descriptions of the trade 

characteristics used to identify the 

potential residual portfolio and of the 

resulting trades (or categories of 

trades).58 A dealer firm should assess 

the risk profile of the potential residual 

portfolio (including its anticipated size, 

composition, complexity, 

counterparties) and the potential 

counterparty and market impacts of 

non-performance on the stability of U.S. 

financial markets (e.g., on funding 

markets and the underlying asset 

markets and on clients and 

counterparties). 

Non-surviving entity analysis. To the 

extent the preferred resolution strategy 

assumes a material derivatives entity 

enters its own resolution proceeding 

after the entry of the parent company 

into a bankruptcy proceeding (a ‘‘nonsurviving material derivatives entity’’), 

the dealer firm should provide a 

detailed analysis of how the nonsurviving material derivatives entity’s 

resolution can be accomplished within 

a reasonable period of time and in a 

manner that substantially mitigates the 

risk of serious adverse effects on U.S. 

financial stability and to the orderly 

execution of the firm’s preferred 

resolution strategy. In particular, the 

firm should provide an analysis of the 

potential impacts on funding markets 

and the underlying asset markets, on 

clients and counterparties (including 

affiliates), and on the preferred 

resolution strategy. If the non-surviving 

material derivatives entity is located in, 

or provides more than de minimis 

services to clients or counterparties 

located in, a non-U.S. jurisdiction, then 

the analysis should also specifically 

consider potential local market impacts. 

VIII. PUBLIC SECTION 

The purpose of the public section is 

to inform the public’s understanding of 

the firm’s resolution strategy and how it 

works. 

The public section should discuss the 

steps that the firm is taking to improve 

resolvability under the U.S. Bankruptcy 

Code. The public section should 

provide background information on 

each material entity and should be 

enhanced by including the firm’s 

rationale for designating material 

entities. The public section should also 

discuss, at a high level, the firm’s intragroup financial and operational 

interconnectedness (including the types 

of guarantees or support obligations in 

place that could impact the execution of 

the firm’s strategy). There should also be 

a high-level discussion of the liquidity 

resources and loss-absorbing capacity of 

the firm. 

The discussion of strategy in the 

public section should broadly explain 

how the firm has addressed any 

deficiencies, shortcomings, and other 

key vulnerabilities that the Agencies 

have identified in prior Plan 

submissions. For each material entity, it 

should be clear how the strategy 

provides for continuity, transfer, or 

orderly wind-down of the entity and its 

operations. There should also be a 

description of the resulting organization 

upon completion of the resolution 

process. 

The public section may note that the 

resolution plan is not binding on a 

bankruptcy court or other resolution 

authority and that the proposed failure 

scenario and associated assumptions are 

hypothetical and do not necessarily 

reflect an event or events to which the 

firm is or may become subject. 

By the Board of Governors of the Federal 

Reserve System, June 28, 2018. 

Ann E. Misback, 

Secretary of the Board. 

Dated at Washington, DC on June 28, 2018. 

By order of the Board of Directors. 

Federal Deposit Insurance Corporation. 

Valerie Jean Best, 

Assistant Executive Secretary. 

[FR Doc. 2018–15066 Filed 7–13–18; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Meeting of the National Advisory 

Council for Healthcare Research and 

Quality 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), HHS. 

ACTION: Notice of public meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, this 

notice announces a meeting of the 

National Advisory Council for 

Healthcare Research and Quality. 

DATES: The meeting will be held on 

Wednesday, July 18, 2018, from 8:30 

a.m. to 2:45 p.m. 

ADDRESSES: The meeting will be held at 

AHRQ, 5600 Fishers Lane, Rockville, 

Maryland, 20857. 

FOR FURTHER INFORMATION CONTACT: 

Jaime Zimmerman, Designated 

Management Official, at the Agency for 

Healthcare Research and Quality, 5600 

Fishers Lane, Mail Stop 06E37A, 

Rockville, Maryland 20857, (301) 427– 


sradovich on DSK3GMQ082PROD with NOTICES
32872 Federal Register / Vol. 83, No. 136 / Monday, July 16, 2018 / Notices 

1456. For press-related information, 

please contact Alison Hunt at (301) 427– 

1244 or Alison.Hunt@ahrq.hhs.gov. 

If sign language interpretation or other 

reasonable accommodation for a 

disability is needed, please contact the 

Food and Drug Administration (FDA) 

Office of Equal Employment 

Opportunity and Diversity Management 

on (301) 827–4840, no later than 

Tuesday, July 3, 2018. The agenda, 

roster, and minutes will be available 

from Ms. Bonnie Campbell, Committee 

Management Officer, Agency for 

Healthcare Research and Quality, 5600 

Fishers Lane, Rockville, Maryland 

20857. Ms. Campbell’s phone number is 

(301) 427–1554. 

SUPPLEMENTARY INFORMATION: 

I. Purpose 

The National Advisory Council for 

Healthcare Research and Quality is 

authorized by Section 941 of the Public 

Health Service Act, 42 U.S.C. 299c. In 

accordance with its statutory mandate, 

the Council is to advise the Secretary of 

the Department of Health and Human 

Services and the Director of AHRQ on 

matters related to AHRQ’s conduct of its 

mission including providing guidance 

on (A) priorities for health care research, 

(B) the field of health care research 

including training needs and 

information dissemination on health 

care quality and (C) the role of the 

Agency in light of private sector activity 

and opportunities for public private 

partnerships. The Council is composed 

of members of the public, appointed by 

the Secretary, and Federal ex-officio 

members specified in the authorizing 

legislation. 

II. Agenda 

On Wednesday, July 18, 2018, the 

Council meeting will convene at 8:30 

a.m., with the call to order by the 

Council Chair and approval of previous 

Council summary notes. The meeting is 

open to the public and will be available 

via webcast at www.webconferences. 

com/ahrq. The meeting will begin with 

an update on AHRQ’s current research, 

programs, and initiatives. The agenda 

will also include updates on: AHRQ 

Data, Analytics, and Insights; Making 

Health Services Research Relevant to 

the C-Suite; and AHRQ’s Opioids 

efforts. The final agenda will be 

available on the AHRQ website at 

www.AHRQ.gov no later than Friday, 

July 13, 2018. 

Francis D. Chesley, Jr., 

Acting Deputy Director. 

[FR Doc. 2018–15105 Filed 7–13–18; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

AGENCY: Agency for Healthcare Research 

and Quality, HHS. 

ACTION: Notice. 

SUMMARY: This notice announces the 

intention of the Agency for Healthcare 

Research and Quality (AHRQ) to request 

that the Office of Management and 

Budget (OMB) approve the proposed 

information collection project 

‘‘Consumer Assessment of Healthcare 

Providers and Systems (CAHPS) 

Clinician and Group Survey Database.’’ 

DATES: Comments on this notice must be 

received by September 14, 2018. 

ADDRESSES: Written comments should 

be submitted to: Doris Lefkowitz, 

Reports Clearance Officer, AHRQ, by 

email at doris.lefkowitz@AHRQ.hhs.gov. 

Copies of the proposed collection plans, 

data collection instruments, and specific 

details on the estimated burden can be 

obtained from the AHRQ Reports 

Clearance Officer. 

FOR FURTHER INFORMATION CONTACT: 

Doris Lefkowitz, AHRQ Reports 

Clearance Officer, (301) 427–1477, or by 

emails at doris.lefkowitz@

AHRQ.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

Proposed Project 

Renewal of the Consumer Assessment of 

Healthcare Providers and Systems 

(CAHPS) Clinician and Group Survey 

Database 

In accordance with the Paperwork 

Reduction Act, 44 U.S.C. 3501–3521, 

AHRQ invites the public to comment on 

this proposed information collection. 

The CAHPS Database is a repository for 

data from selected CAHPS surveys. The 

primary purpose of the CAHPS Database 

is to facilitate comparisons of CAHPS 

survey results by survey users. This 

voluntary compilation of survey results 

from a large pool of data into a single 

database enables survey users to 

compare their own results to relevant 

Database results. The CAHPS Database 

also offers an important source of 

primary data for research related to 

consumer assessments of quality as 

measured by CAHPS surveys. 

The CAHPS Clinician & Group Survey 

(CG–CAHPS) Database is the newest 

component of the CAHPS Database. It 

was developed in response to the 

growing demand for Database results for 

the various versions of the CG–CAHPS 

Survey, including the 12-month and 

Visit versions. In May 2011, the first set 

of Database results for both the 12- 

month and Visit versions was released 

through the CAHPS Database Online 

Reporting System. 

AHRQ developed the database for 

CAHPS CG Survey data following the 

CAHPS Health Plan Database as a 

model. The CAHPS Health Plan 

Database was developed in 1998 in 

response to requests from health plans, 

purchasers, and CMS for survey data to 

support public reporting of health plan 

ratings, health plan accreditation and 

quality improvement (OMB Control 

Number 0935–0165, expiration 5/31/ 

2020). Demand for survey results from 

the CG Survey has grown as well, and 

therefore AHRQ developed a dedicated 

Clinician and Group Database to 

support benchmarking, quality 

improvement, and research (OMB 

Control Number 0935–0197, expiration 

02/28/2019). 

The CAHPS Database contains data 

from AHRQ’s standardized CAHPS 

Surveys which provide survey measures 

of quality to health care purchasers, 

consumers, regulators, and policy 

makers. The Health Plan Database also 

provides data for AHRQ’s annual 

National Healthcare Quality and 

Disparities Reports. 

The goal of this project is to renew the 

CAHPS CG Survey Database. This 

database will continue to update the 

CAHPS CG Database with the latest 

results of the CAHPS CG Survey. These 

results consist of 31 items that measure 

5 areas or composites of patients’ 

experiences with physicians and staff in 

outpatient medical practices. This 

database can be used to do the 

following: 

(1) Improve care provided by 

individual providers, sites of care, 

medical groups, or provider networks. 

(2) Offer several products and 

services, including providing survey 

results presented through an Online 

Reporting System, summary chartbooks, 

custom analyses, private reports in 

Excel format, and data for research 

purposes. 

(3) Provides information to help 

identify strengths and areas with 

potential for improvement in patient 

care. The five composite measures are: 

Getting Timely Appointments, Care, and 

Information 

How Well Providers Communicate With 

Patients 

Helpful, Courteous, and Respectful 

Office Staff 

Providers’ Use of Information to 

Coordinate Patient Care 


sradovich on DSK3GMQ082PROD with NOTICES